

On the Reversal of Myocardial Stunning: A Role for Ca²⁺-Sensitizers

DONGSHENG FAN, LOE KIE SOEI,
LOES M. A. SASSEN, ROB KRAMS,
EDWIN HENDRIK, AND
PIETER D. VERDOUW^a

*Experimental Cardiology, Thomaxcenter
Cardiovascular Research Institute (COEUR)
Erasmus University Rotterdam
P.O. Box 1738
3000 DR Rotterdam
The Netherlands*

INTRODUCTION

The mechanism underlying myocardial stunning is still unknown, but current views hold that generation of free radicals and disturbances in the calcium homeostasis, mechanisms which are not mutually exclusive, are the two most likely causes of prolonged postischemic dysfunction.^{1,2} Several groups of investigators have indeed shown that the capacity of cardiac sarcoplasmic reticulum (SR) to sequester Ca²⁺ decreases during ischemia.^{3,4} In a recent study we have shown that the phosphorylation rate of phospholamban was unchanged, and that Ca²⁺ uptake by the sarcoplasmic reticulum was even slightly increased in myocardium of intact open-chest pigs, while function was still reversibly depressed.⁵ These data and earlier work by Marban and coworkers⁶ in isolated stunned ferret hearts strongly suggest that a decreased response of the myofilaments to Ca²⁺ rather than a change in the active Ca²⁺ transport of the SR is involved in the contractile dysfunction of stunned myocardium. *In vivo* evidence of this hypothesis has been very difficult to obtain because available agents that increase the responsiveness of the myofilaments to Ca²⁺ usually also increase contractility via inhibition of phosphodiesterase. We now report on the effects of the thiadiazinone derivative EMD 60263, which in *in vitro* experiments has been shown to be a potent Ca²⁺ sensitizer devoid of any phosphodiesterase inhibiting properties (Ravens *et al.*, unpublished data). The compound also affects the delayed rectifier current I_{Kr} in a way characteristic for a class III antiarrhythmic action. The latter property may lead to a reduction in heart rate.

^a To whom correspondence should be addressed.

MATERIALS AND METHODS

Pigs (28–30 kg) were anesthetized and instrumented as described earlier.⁷ After a stabilization period the left anterior descending coronary artery (LADCA) was occluded for 10 min and reperfused for 30 min. This sequence of occlusion and reperfusion was then repeated. At the end of the second 30-min reperfusion period, two consecutive infusions of either saline (3 ml and 6 ml; $n = 6$) or EMD 60263 (1.5 mg/kg and 3.0 mg/kg, $n = 7$; courtesy of Dr. I. Lues and Prof. Dr. P. Schelling, E. Merck, Darmstadt, FRG) were administered at 15-min intervals and the effects on systemic hemodynamics, regional myocardial segment length shortening (SLS) of the myocardium perfused by the LADCA and the left circumflex coronary artery (LCXCA), and regional myocardial blood flow were measured. The area of the pressure-segment length loop was calculated as an index of external work (EW),⁸ while the mechanical efficiency was determined as the ratio of EW and $M\dot{V}O_2$, in which the $M\dot{V}O_2$ is the regional myocardial oxygen consumption (i.e., the product of regional transmural myocardial blood flow and the difference in the arterial and local coronary venous oxygen content).

TABLE 1. The Effects of EMD 60263 on Systemic Hemodynamics in Anesthetized Pigs with Stunned Myocardium

	EMD 60263	Baseline	Stunning	3 ml 1.5 mg/kg	6 ml 3.0 mg/kg
Heart rate (beats/min)	Saline	107 ± 3	103 ± 7	103 ± 8	101 ± 8
	EMD 60263	107 ± 5	97 ± 3*	69 ± 2 [†] #	50 ± 3 [†] #
Systolic arterial pressure (mm Hg)	Saline	109 ± 2	101 ± 3*	101 ± 2	107 ± 3 [†]
	EMD 60263	114 ± 2	108 ± 3	106 ± 3	111 ± 4
Diastolic arterial pressure (mm Hg)	Saline	77 ± 2	73 ± 3*	72 ± 2	75 ± 2
	EMD 60263	83 ± 3	79 ± 4	67 ± 4 [†] #	62 ± 3 [†] #
Cardiac output (L/min)	Saline	2.9 ± 0.3	2.4 ± 0.1*	2.4 ± 0.2	2.4 ± 0.1
	EMD 60263	2.9 ± 0.1	2.5 ± 0.1*	2.3 ± 0.1	2.2 ± 0.1 [†]
Stroke volume (ml)	Saline	27 ± 2	23 ± 1	23 ± 1	24 ± 1
	EMD 60263	27 ± 2	26 ± 1	33 ± 2 [†] #	45 ± 3 [†] #
Systemic vascular resistance (mm Hg·min/L)	Saline	32 ± 3	35 ± 2*	35 ± 3	36 ± 3
	EMD 60263	33 ± 3	36 ± 3	36 ± 3	36 ± 3
Left ventricular dP/dt _{max} (mm Hg/sec)	Saline	2070 ± 220	1580 ± 180*	1600 ± 170	1640 ± 160
	EMD 60263	2130 ± 150	1580 ± 110*	1520 ± 110	1630 ± 100
Left ventricular end diastolic pressure (mm Hg)	Saline	8 ± 1	9 ± 1	8 ± 1	10 ± 2
	EMD 60263	10 ± 1	10 ± 1	11 ± 1	14 ± 2 [†]

$n = 6$ for the saline-treated animals; $n = 7$ for the EMD 60263-treated animals; * $p < 0.05$ stunning versus baseline; [†] $p < 0.05$ versus stunning; # Changes versus stunning are significantly different from changes versus stunning in saline-treated animals; Data are mean ± SEM.




FIGURE 1. The effects of EMD 60263 on segment length shortening (SLS) and external work (EW) of the myocardium perfused by the left anterior descending coronary artery (LADCA) and the myocardium perfused by the left circumflex coronary artery (LCXCA) and the mechanical efficiency (EW/MVO₂) of the LADCA-perfused myocardium. *n* = 6 for the saline-treated animals; *n* = 7 for the EMD 60263-treated animals; * *p* < 0.05 stunning versus baseline; + *p* < 0.05 versus stunning; # changes versus stunning are significantly different from changes versus stunning in saline-treated animals. Data are mean ± SEM.

RESULTS AND DISCUSSION

Induction of myocardial stunning was accompanied by the well-described changes in systemic hemodynamic variables (TABLE 1). In the saline-treated animals there were no further changes in any of these variables during the following 30 min. Administration of EMD 60263 caused a number of changes of which the decreases in heart rate and diastolic arterial pressure and the increase in stroke volume were the most pronounced.

An additional consequence of the occlusion-reperfusion protocol was that in the stunned myocardium systolic SLS, EW, and the EW/MVO₂ were reduced by approximately 50% (FIG. 1). No changes occurred in the area perfused by the LCXCA. All regional function variables remained stable in the saline-treated animals during the following 30 min (FIG. 1). In the stunned myocardium, administration of EMD 60263 caused dose-dependent increases in all variables, with the values for SLS and EW exceeding the data obtained at baseline. In the control segment some variables also increased, but, most importantly, all differences in the variables between the stunned and the control regions disappeared.

In order to exclude that changes in regional function were secondary to changes in heart rate or adrenergic stimulation, we studied in separate experiments, using the same model, the effects of the specific negative chronotropic drug zatebradine (UL-FS 49)⁹ and the effects of EMD 60263 after blockade of the α - and β -adrenoceptors and observed that bradycardia did not improve function of the stunned myocardium and that adrenergic stimulation did not contribute to the effect of EMD 60263.

We conclude that these experiments, although not providing definite proof, lend further support to the hypothesis that a decrease in the sensitivity of the myofilaments to Ca²⁺ plays a role in the mechanism leading to myocardial stunning.

REFERENCES

1. HEARSE, D. J. 1991. *Cardiovasc. Drugs Ther.* **5**: 853-876.
2. BOLLI, R. 1990. *Circulation* **82**: 723-738.
3. KRAUSE, S. M., W. E. JACOBUS & L. C. BECKER. 1989. *Circ. Res.* **65**: 526-530.
4. SCHOUTSEN, B., J. J. BLOM, P. D. VERDOUW & J. M. J. LAMERS. 1989. *J. Mol. Cell Cardiol.* **21**: 719-727.
5. LAMERS, J. M. J., D. J. DUNCKER, K. BEZSTAROSTI, E. O. MCFALLS, L. M. A. SASSEN & P. D. VERDOUW. 1993. *Cardiovasc. Res.* **27**: 520-524.
6. MARBAN, E., Y. KORETSUNE, M. CORRETTI, V. P. CHACKO & H. KUSUOKA. 1989. *Circulation* **80**: IV17-IV22.
7. DUNCKER, D. J., E. O. MCFALLS, R. KRAMS & P. D. VERDOUW. 1992. *Am J. Physiol.* **262** (Heart Circ. Physiol. 31): H1744-H1751.
8. KRAMS, R., D. J. DUNCKER, E. O. MCFALLS, A. HOGENDOORN & P. D. VERDOUW. 1993. *Cardiovasc. Res.* **27**: 740-747.
9. VAN WOERKENS, L. J., W. J. VAN DER GIESSEN & P. D. VERDOUW. 1992. *Cardiovasc. Drugs Ther.* **6**: 59-65.